Recent studies have shown that the lncRNA MEG3 is associated with glioma, Huntington's disease, stroke, and other neurological disorders, suggesting a potentially new clinical biomarker (15, 16), it can block the cell cycle by activating the p53 pathway, leading to cell replication senescence or apoptosis. This evidence concerns the gene MEG3 and central nervous system cancer.